CD19 and neoplasm: At the same time, most tumor-associated antigens are also expressed at low levels in normal tissues, creating a risk of on-target, off-tumor toxicity; for example, CD19 CAR-T cells deplete both malignant and healthy B cells, causing B cell aplasia that necessitates long-term immunoglobulin replacement therapy [135].